The occurrence of fused anaplastic lymphoma kinase (ALK) gene in NSCLC patients is ~5% in western countries, but ALK mutations have become the second most significant molecular mutations in the regimen of NSCLC treatment following epidermal growth factor receptor (EGFR) mutations (2–6). Here, ALK is linked to non-small cell lung carcinoma.